Galena Biopharma, Inc. (NASDAQ:GALE) Given Hold Rating at Maxim Group
Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Galena Biopharma from a buy rating to a hold rating in a research note on Tuesday, May 16th. ValuEngine lowered Galena Biopharma from a sell rating to a strong sell rating in a research note on Friday, June 2nd.
Shares of Galena Biopharma (GALE) traded down 5.7119% during mid-day trading on Wednesday, hitting $0.3384. The stock had a trading volume of 792,563 shares. Galena Biopharma has a 1-year low of $0.26 and a 1-year high of $9.10. The company has a market capitalization of $13.07 million, a P/E ratio of 1.3015 and a beta of 1.77. The stock’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.67.
Galena Biopharma (NASDAQ:GALE) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.13. During the same period in the prior year, the business posted ($0.07) EPS. On average, analysts predict that Galena Biopharma will post ($0.56) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Galena Biopharma, Inc. (NASDAQ:GALE) Given Hold Rating at Maxim Group” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/13/galena-biopharma-inc-nasdaqgale-given-hold-rating-at-maxim-group.html.
Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Galena Biopharma by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 13,302 shares during the period. Virtu KCG Holdings LLC raised its stake in shares of Galena Biopharma by 677.4% in the second quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 195,230 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Galena Biopharma during the first quarter valued at about $976,000. 21.99% of the stock is owned by institutional investors.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Stock Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related stocks with our FREE daily email newsletter.